Tomosynthesis mammography has moved from emerging technology to standard of care in most breast imaging programs, and facilities still running 2D-only digital mammography face both a clinical and a competitive gap that grows each year. The Fujifilm ASPIRE Cristalle is Fujifilm Medical's full-field digital mammography platform with integrated tomosynthesis, and breast centers that have deployed it report that the image quality on dense breast tissue and the workflow integration with their PACS environments met their expectations. We finance ASPIRE Cristalle systems for breast health programs of every size.
The ASPIRE Cristalle uses Fujifilm's CsI (cesium iodide) flat-panel detector with a pixel pitch of 50 microns, which Fujifilm positions as delivering high spatial resolution across the full mammography field. The tomosynthesis acquisition on the Cristalle sweeps the tube through a defined arc and reconstructs slice images at 1 mm intervals through the breast volume. The reconstructed slices are reviewed alongside a synthetic 2D image generated from the tomo dataset, eliminating the second full-dose 2D acquisition that older combo-mode systems required. The detector technology and the tomo reconstruction together form the clinical case for the Cristalle in a competitive market that includes the Hologic Selenia Dimensions, the Siemens Mammomat Revelation, and the Philips MicroDose SI.
ASPIRE Cristalle Clinical Design and Detector Technology
The 50-micron pixel pitch on the Cristalle's CsI detector is a design specification Fujifilm highlights for fine-detail visualization in the breast parenchyma and microcalcification detection. Standard 2D mammography detectors across the major platforms range from 70 to 100 micron pixel pitch, so the Cristalle's finer pitch is a genuine technical differentiator on paper, though the clinical impact in practice depends on the full image chain including the anti-scatter grid, the compression paddle, and the display calibration at the reading station.
The C-arm design on the Cristalle accommodates standard screening and diagnostic compression paddles, spot compression paddles, and magnification stands for localized diagnostic work. The patient comfort features include a motorized height-adjustable arm and a design that Fujifilm has optimized for patient positioning assistance from the technologist without requiring manual compression handle adjustment during positioning.
Fujifilm's Workflow Intelligence software integrates with the Cristalle to manage worklist routing, acquisition protocol selection, and PACS export. The integration supports most major PACS platforms through standard DICOM connections, and the system is validated for use with most commercial CAD (computer-aided detection) software packages that breast radiologists use in their reading workflow.
The ASPIRE Cristalle competes directly with the Siemens Mammomat Revelation and the Philips MicroDose SI in the premium mammography segment. The Hologic Selenia Dimensions and 3Dimensions systems, covered on the Hologic mammography financing page, are also direct competitors. Each platform has strengths worth evaluating before committing to a capital purchase of this size.
New Versus Pre-Owned ASPIRE Cristalle
A new ASPIRE Cristalle prices running about $300k to $500k for the system with installation and software, depending on configuration and whether a stereotactic biopsy option is included. New systems carry the full Fujifilm manufacturer warranty and the current software version, including the most recent tomo reconstruction algorithms and display processing updates.
Pre-owned Cristalle units do appear on the secondary market, primarily from hospitals and imaging centers upgrading to newer software versions or replacing equipment for other operational reasons. A certified pre-owned Cristalle with documented service history and a verified detector can be a cost-effective path for practices entering the tomosynthesis market on a tighter budget. We finance pre-owned ASPIRE Cristalle units under our used equipment financing program, with equipment age and condition report requirements that match what we apply to other used mammography systems.
For practices comparing a used Cristalle to a new entry-level tomosynthesis system from a different manufacturer, the relevant question is total project cost versus clinical capability. A used Cristalle with full tomo capability and a documented service record may outperform a new system on value per clinical feature, or a new platform may be preferable for service contract coverage and upgrade path certainty. We can structure financing on either approach and help you compare the monthly payments before you decide.
Programs That Finance the ASPIRE Cristalle
Breast health centers replacing an older 2D FFDM unit with a tomo-capable system make up the largest share of ASPIRE Cristalle buyers. The upgrade from 2D to tomosynthesis is now a standard recommendation in dense breast tissue markets, and the Cristalle is positioned as a full-capability replacement in that upgrade cycle.
Women's health and OB/GYN practices that want to bring mammography in-house and give their patients access to tomosynthesis without referring out to a separate imaging center are a strong buyer profile. Adding in-house mammography changes the practice's revenue model and keeps the patient relationship inside the practice rather than sharing it with an outside imaging group.
Hospital breast programs adding a second mammography room to reduce wait times or opening a dedicated breast health pavilion often choose between the Cristalle and competing Hologic or Siemens platforms. We finance all of them and can put financing terms on each side by side so the comparison includes capital cost and monthly cash obligation together. Practices that are new to the mammography market can access our new practice startup financing program if the business has limited operating history but strong personal credit and clinical credentials.
Related Financing Paths
Questions about Fujifilm ASPIRE Cristalle Mammography Financing
Clear answers on equipment eligibility, documentation, timing, and the financing path before you send the full file.
Does the ASPIRE Cristalle tomosynthesis acquisition require a separate full-dose 2D exposure, or is the synthetic 2D generated from the tomo data?
The ASPIRE Cristalle generates a synthetic 2D mammogram from the tomosynthesis acquisition data, eliminating the need for a separate full-field 2D exposure. This single-acquisition approach reduces the total dose per study compared to systems that require both a 2D acquisition and a separate tomo sweep. Some practices still acquire a conventional 2D alongside the tomo for reading preference reasons, which is possible but not required by the system.
Can we add a stereotactic biopsy option to the ASPIRE Cristalle at a later date, and can that addition be financed separately?
Fujifilm offers stereotactic biopsy add-on options compatible with the ASPIRE Cristalle. Adding one after initial installation is possible if the original purchase included the necessary hardware provisions. The biopsy add-on can be financed as a separate equipment upgrade at the time of addition, with its own loan or lease structure.
We are a hospital system buying three ASPIRE Cristalle units for three facilities. Can we structure a single credit approval for all three?
Multi-unit purchases across a health system can be structured under a single master credit facility or as a blanket approval that covers multiple drawdowns. Large multi-facility transactions require full financial statement documentation regardless of the per-unit amount and are typically underwritten at the enterprise level rather than per-facility. We handle multi-location medical system financing regularly.
What happens to the financing if Fujifilm releases a significant software upgrade after we take delivery?
Software upgrade pricing and timing are a matter between your practice and Fujifilm's service agreement. Financing is structured around the equipment value, not the software version. If an upgrade requires a hardware component replacement, that would be evaluated separately. Most major software updates are covered under Fujifilm's service and support agreements for systems under warranty or extended contract.
Is deferred payment financing available so we are not making loan payments before the system is fully installed and generating revenue?
Yes. Some lenders offer a 90-day payment deferral that delays the first payment until the system has had time to ramp up exam volume. The deferral does add a small cost to the total finance package, but for breast programs opening a new location or room, the ability to align the first payment with initial revenue is often worth the incremental interest cost.
Bring this system into your room.
Send the Fujifilm ASPIRE Cristalle Mammography Financing quote, seller details, requested amount, and installation target. The imaging finance desk will map the next practical step.